Jun 29, 2020

Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on Private Insurance

Posted by in category: biotech/medical


Gilead’s Covid-19 drug remdesivir will be priced at $3,120 for a typical U.S. patient with commercial insurance.

Gilead Sciences Inc. detailed its pricing plans for Covid-19 drug remdesivir, saying it will charge U.S. hospitals $3,120 for a typical patient with commercial insurance.

The drugmaker on Monday disclosed its pricing plans as it prepares to begin charging for the drug in July. The U.S. has been distributing remdesivir donated by Gilead since the drug was authorized for emergency use in May.

Comments are closed.